Cancer therapeutics company ValiRx been given the green light on a European patent for its Nucleosomics technology patent application. The move follows the signing of a licence agreement in October with Chroma Therapeutics to commercialise Nucleosomics, a non-invasive diagnostic technology patent developed by Chroma.
